In case you missed it in The Sun the week of May 19, 2025
www.jamestownsun.com
and in The Jamestown Sun.
Students, faculty, staff and administrators of Victory Christian School as well as parents and Jamestown Area Chamber of Commerce ambassadors
marked the completion of the school's new addition
on Friday, May 16, with a ribbon-cutting ceremony.
"It's going to benefit the church and benefit the community of Jamestown to have this space," said Mike Woodley, executive director of Victory Christian School.
Beginning this fall, Victory Christian School will offer classes for students prekindergarten through ninth grade. The school offered classes for students prekindergarten through eighth grade this past school year.
A new grade will be added each year with the addition of 12th grade in 2028.
Victory Christian School launched its $5 million "Growing Together" capital campaign in April 2024 for the construction of the new addition with a goal of starting a high school. Woodley said $4.2 million has been raised of the $5 million goal.
The Stutsman County Commission in a 4-0 vote on Tuesday, May 20,
appointed Benjamin Tompkins
to serve on the board.
Tompkins was one of 11 applicants who applied to fill the vacant seat on the county commission."I'm very excited," Tompkins said. "I think that I can bring a lot of perspective that not everybody gets to see."
The other applicants were George Barnes, John Baumgartner, Paul Belzer, Dernel Denning, Steven Gerszewski, John Grabinger, Daren Peterka, Trever Sahr, Taylor Vining and Alan Williams.
Tompkins took the oath of office and filled the vacant seat after he was appointed on Tuesday.
The vacancy was created after the death of Commissioner Jerry Bergquist on April 24. Bergquist was elected to the commission in November 2022.
Tompkins will hold the office at least until the next general election. North Dakota Century Code 44-02-05 says the appointee holds office until the appointee's successor is elected at the next general election that occurs at least 95 days after the vacancy and the successor has qualified. The next general election cycle is in 2026.
The Jamestown Building, Planning and Zoning Committee unanimously recommended approval on Tuesday, May 20, of
a minor subdivision in northeast Jamestown
.
The final plat of the Buffalo Estates First Addition is a replat of a portion of Horizon Estates First Addition. Buffalo Estates First Addition is located east of the Two Rivers Activity Center between 25th and 27th Avenue Northeast and north of 5th Street Northeast. There is no street for 25th Avenue Northeast at the location.
In related business, the Building, Planning and Zoning Committee unanimously recommended approval of the future land use plan amendment for Buffalo Estates First Addition from vacant/agricultural to a single-family residential district. The committee also unanimously recommended approval to introduce the first reading of an ordinance to amend and reenact ordinance No. 1556 of the city code by amending the district map to change the zoning of blocks one and two of the Buffalo Estates First Addition from a one-family residential district to a one-family residential and duplex or two-family residential district.
The reason for the requests of the future land use plan and zoning map amendments is "to have the optimum ability to develop the area between single-family homes and single-family attached homes," according to the applications.
The Jamestown chief of police says an ordinance is needed that would impose fees
for repeat offenders of false burglar or fire alarms
at businesses in Jamestown.
Scott Edinger, chief of police, told the Jamestown Police and Fire Committee on Thursday, May 22, that the discussion for an ordinance is in the preliminary stages. He said the Jamestown Police Department has responded to an average of 218 false alarm calls per year for the past 10 years. In a letter to the Jamestown City Council, Edinger wrote that less than 0.25% of the alarms the Jamestown Police Department responds to have any actual emergency involved.
Edinger said many of the false burglar alarm calls are at the same businesses.
Fire Chief Jim Reuther said the Jamestown Fire Department is also experiencing a lot of false fire alarm calls.
Mayor Dwaine Heinrich said city staff should research what can be put in an ordinance and present it to the City Council.
Edinger said the ordinance should be in place starting on Jan. 1, 2026.
"That gives us an opportunity to get this information out to the businesses," he said.
No action was taken on the issue.
The status of funding for Northern Prairie Wildlife Research Center and other facilities operated by the U.S. Geological Survey through its Ecosystems Mission Area
is still unclear
even after the House of Representatives passed the Trump administration-sponsored budget bill on Thursday, May 22.
Sen. John Hoeven's office replied in an email to a request for information before the budget bill passed the House of Representatives by saying, "We checked with the Department of the Interior regarding the Northern Prairie Wildlife Research Center. DOI is evaluating their facility options and no budget decisions have been made at this point regarding staffing or funding."
Rep. Julie Fedorchak's office did not provide information regarding the status of funding for the Ecosystems Mission Area the morning after the budget bill passed during the overnight hours.
Various media outlets and national and regional wildlife and ecological organizations have reported that the Ecosystems Working Group and its laboratories around the country will be eliminated as part of budget cuts going into the next federal fiscal year, which starts Oct. 1.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Enlivex advances lead cell therapy to Phase IIb in osteoarthritis
Enlivex Therapeutics is planning to advance its lead cell therapy asset, Allocetra, to Phase IIb trials following the positive results from the primary group of its Phase I/IIa study in knee osteoarthritis (KOA). Though the resident macrophage-targeting therapy failed to have a statistically significant impact on the study's entire patient population, three biweekly doses of the drug were shown to statistically reduce Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores associated with knee pain, function and stiffness in a primary osteoarthritis (POA) population. During the ENX-CL-05-001 (NCT06233474) study, the POA group – which is categorised by disease onset due to ageing and general joint wear and tear – experienced a 72% reduction in WOMAC knee pain scores compared to placebo, while function scores increased by 95%. Both figures were statistically significant, with p values of 0.03 and 0.007, respectively. Allocetra also significantly improved WOMAC stiffness and function change, as well as pain and function change scores – boosting these by 47% and 49%, respectively. Following the positive results of the Phase I/IIa trial, Enlivex plans to obtain regulatory approval from the US Food and Drug Administration (FDA) for a Phase IIb trial of Allocetra, which the company estimates will come by Q2 of 2026. According to this timeline, the biopharma expects to dose the first patient in this trial by Q3 of 2026. These results come at a time when there is a strong unmet need for patients with KOA, as the non-surgical current treatment landscape revolves around the use of steroids and non-steroidal anti-inflammatory drugs (NSAIDs) like naproxen and ibuprofen. Though there are limited treatment options available for patients, the osteoarthritis market was worth $2.5 billion in 2021, according to a report by the parent company of Clinical Trials Arena, GlobalData. However, to be successful in this indication, Allocetra may have to fend off competition from other drug candidates moving forward, as there are currently 30 ongoing Phase III clinical trials assessing the efficacy of biologic drugs for osteoarthritis. This includes R-Biopharm's autologous stem cell therapy, JointStem, which was granted Breakthrough Therapy designation by the US Food and Drug Administration (FDA) in March 2025. "Enlivex advances lead cell therapy to Phase IIb in osteoarthritis" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Boston Globe
2 days ago
- Boston Globe
Suffolk Sheriff Steven Tompkins's arraignment on extortion charges pushed to Thursday
Tompkins, a prominent Democrat in Boston political circles, was arrested earlier this month in Florida for allegedly pressuring the company under the threat of revoking a partnership with his office that was central to its licensing application. Prosecutors allege that in addition to forcing a company official to sell him stock for $50,000 before the venture went public, Tompkins subsequently demanded he be repaid after the value of his shares sank below his initial investment. Advertisement Tompkins has served as sheriff since 2013, overseeing the Nashua Street and South Bay jails in Boston and other detention operations in Suffolk County. He was initially appointed sheriff by former governor Deval Patrick, and then won the seat in the following election. He has been very active in local Democratic politics, offering up Tompkins has not resigned nor given any indication that he plans to in light of the criminal charges, though Advertisement Before he was named sheriff, Tompkins worked as the department's chief of external affairs and created the Common Ground Institute, a vocational training program for inmates about to be released, as well as The Choice Program, which sends correctional officers into Boston's public schools. As part of the legislation that shaped the cannabis industry in Massachusetts, the state requires businesses, as part of the licensing process, to lay out plans to promote diversity and invest in individuals and communities disproportionately affected by previous cannabis prohibitions. Federal prosecutors allege a cannabis company hoping to open in Boston sought to meet that licensing requirement through an agreement with Tompkins to train and hire people recently released from jail. But Tompkins used that partnership to extort the stock deal, prosecutors allege. The indictment of Tompkins didn't name the cannabis company. But a person familiar with the matter confirmed it is Ascend Mass, part of Ascend Cannabis, a multistate retailer whose local operations were once run by Tompkins's close friend Andrea Cabral. Cabral has since left the company. She was previously Suffolk County sheriff, and Tompkins was her top aide. When she was appointed to a statewide post as public safety secretary in late 2012, Patrick tapped Tompkins as her successor. Cabral is not the Ascend official who was allegedly extorted, according to the source, who asked for anonymity because they are not authorized to speak about it publicly. Ascend continues to operate the store in question on Friend Street in Boston, which was relicensed most recently in November, according to the state's Cannabis Control Commission. Material from prior Globe stories was used in this report. Advertisement Travis Andersen can be reached at
Yahoo
2 days ago
- Yahoo
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
- In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including 24% reduction in knee pain and 26% improvement in knee function, were observed in the AllocetraTM treatment arm vs placebo; moreover, 72% reduction in knee pain and 95% improvement in knee function were observed for age-related primary osteoarthritis patients compared with placebo – a substantial, clinically meaningful and statistically significant effect in commonly used Phase III primary endpoints for knee osteoarthritis clinical trials. - Favorable safety profile – No severe adverse events; limited, typically mild to moderate, transient, and treatable side effects occurred in most patients treated with Allocetra™ - Webinar today at 8:00 a.m. Eastern Time Nes-Ziona, Israel, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the 'Company'), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive three-month topline data from the Phase IIa stage of ENX-CL-05-001, a multi-center, two-stage Phase I/II double-blind, randomized, placebo-controlled clinical trial evaluating Allocetra™ in patients with moderate-to-severe knee osteoarthritis. Oren Hershkovitz, Ph.D, CEO of Enlivex, commented, 'We are excited to share the topline three-month data from ENX-CL-05-001. We believe these results provide clear indication that Allocetra™ has the potential to become a novel, safe and effective treatment for knee osteoarthritis, a growing market with significant unmet medical need.' The Company will host a webinar today at 8:00 am Eastern Time to provide in-depth analysis of the results. To join the webinar, please click To join the webinar, please register at: It is suggested participants join the webinar at least 15 minutes prior to the scheduled start time to avoid any delays in attendance. About ENX-CL-05-001ENX-CL-05-001 is a multi-center Phase I/II clinical trial consisting of two stages. The first stage was a Phase I safety run-in, open-label dose escalation phase to characterize the safety and tolerability of Allocetra™ injections to the target knee, in order to identify the dose and injection regimen for the subsequent Phase IIa stage. The Phase IIa stage is a double-blind, randomized, placebo-controlled multi-centered trial. In addition to evaluating safety, the study protocol was designed to efficiently find a strong signal in a responder population to guide future development, and includes an interim statistical evaluation, conducted by an independent third party and blinded to the Company, to assess the potential value of enrollment of up to 50 patients in addition to the original randomized sample size of 130, and its marginal impact on the p-value of the statistical estimation of the total group and specifically to identify a potential responder sub-group. The trial's key efficacy endpoints evaluate joint-pain and joint-function in comparison to placebo at three months, six months and 12 months post treatment. ABOUT KNEE OSTEOARTHRITIS Osteoarthritis is by far the most common form of arthritis, affecting more than 32.5 million Americans and more than 300 million individuals worldwide. About half of knees with ACL injuries develop osteoarthritis within 5 to 15 years. 78 million Americans are projected to have osteoarthritis by the year 2040. Symptomatic knee osteoarthritis is particularly prevalent and disabling, with 40% of men and 47% of women developing knee osteoarthritis in their lifetimes. Osteoarthritis accounts for over one million hospitalizations annually in the United States, primarily for total joint replacement. The burden of osteoarthritis is enormous, and the need for treatments that reduce pain and attendant disability for persons with osteoarthritis is critical. There are currently no medications approved by either the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) that have been demonstrated to arrest, slow or reverse progression of structural damage in the joint. ABOUT ENLIVEX Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening and life debilitating conditions. For more information, visit Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as 'expects,' 'plans,' 'projects,' 'will,' 'may,' 'anticipates,' 'believes,' 'should,' 'would,' 'could,' 'intends,' 'estimates,' 'suggests,' 'target,' 'has the potential to' and other words of similar meaning, including statements regarding expected cash balances, expected clinical trial results, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRATM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex's business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRATM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex's filings with the Securities and Exchange Commission, including in the Company's most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law. ENLIVEX CONTACT Shachar Shlosberger, CFOEnlivex Therapeutics, INVESTOR RELATIONS CONTACT Dave Gentry, CEORedChip Companies Inc.1-407-644-4256ENLV@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
